BOC Sciences provides high-quality, cost-effective custom antibody conjugation services supported by strong R&D expertise in bioconjugation chemistry, linker design, payload handling, purification, and characterization. We prepare and analyze diverse antibody conjugates, including constructs with potent or toxic payloads, while each project is monitored under strict quality assurance and quality control standards.
Antibody conjugation is the covalent linking of an antibody with a functional molecule, such as a drug, nucleic acid, fluorophore, radionuclide, nanoparticle, or affinity tag. It combines the antibody's precise target-recognition ability with the payload's functional effect, creating multifunctional conjugates for targeted delivery, sensitive detection, imaging, separation, and assay development.
BOC Sciences develops antibody-drug conjugates with optimized linker chemistry, controlled drug loading, and reliable analytical confirmation.
We prepare antibody-oligonucleotide conjugates for multiplex detection, DNA-barcoded antibodies, proximity assays, and targeted nucleic acid research.
BOC Sciences combines protein bioconjugation and peptide bioconjugation expertise to preserve recognition and payload function.
Our antibody-polymer conjugate services support polymer attachment for solubility tuning, surface modification, and biointerface applications.
BOC Sciences prepares antibody-fluorophore conjugates for flow cytometry, microscopy, immunofluorescence, and multiplex assay development.
We provide nanoparticle conjugation services to develop antibody-functionalized particles for detection, imaging, enrichment, and material-biology interfaces.
BOC Sciences prepares antibody-magnetic conjugates for immunocapture, target enrichment, separation, and pull-down workflows.
Our biotin labeling service supports streptavidin-based detection, affinity capture, immunostaining, and multiplex assay design.
BOC Sciences helps research teams move from antibody format and payload structure to chemistry selection, controlled conjugation, purification, DAR assessment, binding review, and application-ready conjugates.
BOC Sciences provides customized antibody conjugation, reaction development, linker modification, payload activation, purification, and analytical support for research teams needing functional antibody conjugates. Key categories include:
| Development Stage | Service Scope & Key Outputs |
| Antibody Evaluation | Assessment of antibody format, concentration, buffer composition, purity, aggregation tendency, binding sensitivity, and available functional groups to determine suitable conjugation routes and potential development risks. |
| Linker-Payload Design | Design of cleavable, non-cleavable, hydrophilic, spacer-modified, click-compatible, and site-selective linker-payload systems for drugs, oligonucleotides, proteins, peptides, polymers, dyes, nanoparticles, and biotin tags. |
| Synthesis | Custom synthesis, activation, modification, and purification of linker-payload intermediates, including small-molecule payloads, peptide derivatives, oligonucleotide handles, polymer reagents, and functional labeling groups. |
| Conjugation Process Development | Optimization of lysine, cysteine, click chemistry, enzymatic, glycan-directed, and site-specific conjugation processes by adjusting reaction ratio, pH, buffer, temperature, time, and purification strategy. |
| Conjugate Characterization | Analytical testing by SEC, HIC, IEX, HPLC, LC-MS, UV-Vis, fluorescence spectroscopy, SDS-PAGE, DLS, and binding assays to evaluate loading ratio, monomer content, free payload, aggregation, and target recognition. |
| Formulation Development | Buffer and formulation screening to improve conjugate solubility, stability, aggregation resistance, storage behavior, and application compatibility for assays, imaging, separation, delivery research, or material systems. |
| In Vitro and In Vivo Efficacy Evaluation | Research-stage evaluation of binding activity, cell uptake, payload function, target engagement, imaging signal, capture efficiency, biodistribution, and functional response using suitable in vitro and in vivo models. |
| Safety Evaluation | Safety-oriented assessment of cytotoxicity, hemocompatibility, non-specific binding, aggregation-related effects, payload release behavior, and off-target response to support conjugate optimization and candidate selection. |
Share your antibody format, concentration, buffer, payload structure, reactive handle, target DAR or labeling degree, preferred application, current conjugation problem, and analytical requirements. Our specialists will design a project-specific plan covering chemistry selection, coupling reaction setup, linker compatibility, purification, analytical confirmation, and performance review.
BOC Sciences discusses the project requirements with the client, reviews the antibody format, payload structure, application goals, and testing needs, and then confirms a practical conjugation plan.
Our team prepares or modifies the linker, payload, and antibody materials, then performs the conjugation reaction under optimized conditions to improve coupling efficiency and product consistency.
BOC Sciences tests the conjugate for identity, loading ratio, purity, aggregation, residual payload, and binding activity, and adds in vitro, in vivo, or special product testing when needed.
Clients receive the final antibody conjugate together with testing reports, analytical results, preparation details, and full project records for clear review and downstream research use.
Antibodies may respond poorly to conjugation when reactive residues are sterically restricted, payload solubility is low, buffer components compete with coupling chemistry, or the payload rapidly hydrolyzes before productive attachment. BOC Sciences addresses these issues by evaluating antibody buffer exchange, payload activation state, linker design, molar ratio, pH, temperature, solvent tolerance, and reaction time. We use analytical feedback to distinguish true low coupling from losses caused by purification, precipitation, or inaccurate concentration measurement.
Hydrophobic dyes, drug-like payloads, aromatic linkers, and high labeling density can promote antibody aggregation, especially when the antibody is exposed to organic co-solvents, reducing conditions, or concentrated reaction mixtures. BOC Sciences reduces aggregation risk by adjusting payload equivalents, spacer hydrophilicity, conjugation order, buffer composition, reaction concentration, and purification method. SEC-HPLC, DLS when needed, and visual solubility review help guide selection of the most application-compatible fraction.
Random lysine labeling can generate broad product distributions, while cysteine-based methods require careful reduction control to avoid over-reduction or antibody fragmentation. BOC Sciences compares lysine, cysteine, glycan, click-enabled, and site-specific strategies according to the client's need for speed, homogeneity, payload number, and binding preservation. We use UV-Vis, HIC, SEC, LC-MS, and peptide-level analysis when suitable to guide DAR or labeling degree control.
Conjugation may reduce antibody function if payloads attach near the antigen-binding region, alter charge distribution, block important surface residues, or introduce steric effects that disrupt target recognition. BOC Sciences designs conjugation workflows around the intended assay, choosing linker length, attachment chemistry, labeling density, and purification criteria to preserve binding. When needed, we coordinate application-oriented testing and analytical method optimization to improve signal-to-background performance.
Collaborate with BOC Sciences to access custom antibody conjugation, linker and payload modification, controlled labeling, purification, orthogonal characterization, and application-oriented data packages for research and development programs.
BOC Sciences combines antibody handling, linker chemistry, payload derivatization, biomolecule labeling, and conjugate analysis in a single workflow. This helps clients avoid fragmented project execution and supports better decisions when antibody stability, payload reactivity, linker hydrophobicity, and application performance must be considered together.
We do not apply one conjugation kit to every project. Our scientists compare lysine, cysteine, glycan, enzymatic, click, and site-specific approaches based on antibody format, payload type, target loading, assay readout, binding sensitivity, and purification constraints. This application-first design improves the chance of obtaining a conjugate that works in the client's real workflow.
Antibody conjugates can contain multiple product species that look similar by a single assay. Our analytical platform supports orthogonal review of size, charge, hydrophobicity, molecular mass, free payload, labeling degree, and aggregation. This gives clients clearer evidence for selecting a usable fraction or improving a conjugation condition.
From simple biotinylation to complex antibody-oligo, antibody-polymer, antibody-nanoparticle, antibody-enzyme, and ADC research conjugates, BOC Sciences adapts the workflow to the molecule rather than forcing the molecule into a fixed protocol. We also provide enzyme bioconjugation and related biomolecule modification services for multicomponent systems.
Client Needs: A cell biology group needed an anti-surface-marker IgG1 labeled with a near-infrared dye for multiplex flow cytometry and fixed-cell imaging. Their first attempt produced bright signal but high background and visible aggregation after storage in the assay buffer.
Challenges: The dye was hydrophobic, and the initial lysine labeling workflow generated a broad labeling distribution. Over-labeled fractions showed reduced binding response, while under-labeled fractions gave weak signal in low-abundance target cells.
Solution: We compared three NHS-dye equivalents, two buffer systems, and a hydrophilic spacer-modified dye precursor across 12 reactions. SEC-HPLC and UV-Vis guided fraction selection, while binding response was checked in the client's assay buffer. A moderate labeling ratio with post-reaction desalting and SEC cleanup reduced aggregate formation and improved signal-to-background balance.
Outcome: The client received a dye-labeled antibody fraction with stronger usable signal, lower background, and a clear analytical summary for future labeling batches.
Client Needs: A proteomics team required DNA-barcoded antibodies for a multiplex protein-detection workflow. The antibody panel included both full-length IgG and Fab formats, and several antibodies were available only in stabilizer-containing buffers.
Challenges: Buffer additives interfered with coupling, and early antibody-oligo reactions showed low recovery after purification. The team also needed to distinguish single-oligo conjugates from multi-oligo species to reduce assay variability.
Solution: We first performed buffer exchange and antibody recovery checks, then installed complementary azide and DBCO handles for copper-free click conjugation. Sixteen conjugation conditions were tested across antibody-to-oligo ratios, reaction concentration, and incubation profiles. IEX and SEC were used to enrich single-oligo species, followed by UV-Vis, gel analysis, and LC-MS review.
Outcome: The optimized workflow produced antibody-oligo conjugates with improved recovery and cleaner species distribution for the client's multiplex assay development.
Client Needs: A discovery chemistry group needed a cysteine-linked antibody conjugate bearing a hydrophobic linker-payload analog for comparative internalization studies. The initial conjugation attempt gave poor recovery and significant high-molecular-weight species.
Challenges: Partial disulfide reduction was difficult to control, and the linker-payload analog had limited aqueous solubility. Excess organic co-solvent increased aggregation, while lower co-solvent levels reduced payload incorporation.
Solution: We screened controlled reduction conditions, payload addition sequence, co-solvent percentage, and hydrophilic linker spacing in 20 microscale reactions. SEC-HPLC, HIC, UV-Vis, and intact LC-MS were used to track DAR, residual antibody, and aggregate content. The selected process applied staged payload addition, rapid quenching, and SEC-based fraction selection to protect conjugate quality.
Outcome: The client obtained a cleaner cysteine-linked conjugate with a narrower DAR profile and sufficient analytical evidence for comparing linker-payload behavior.
Antibody conjugation services are suitable for research projects that require antibodies to be linked with functional molecules such as drug payloads, fluorescent dyes, oligonucleotides, peptides, proteins, polymers, nanoparticles, magnetic beads, or biotin. Clients usually need to preserve antigen recognition while introducing a payload with controlled loading, acceptable recovery, and compatibility with downstream detection, imaging, separation, or targeted delivery studies. BOC Sciences designs project-specific conjugation strategies according to antibody format, payload structure, linker chemistry, application goal, and required analytical data.
The choice of conjugation chemistry depends on antibody format, available reactive groups, payload solubility, target labeling degree, desired site control, and how sensitive the downstream application is to background signal or binding loss. Common approaches include lysine conjugation, cysteine conjugation, glycan-directed attachment, enzymatic modification, and click chemistry. Each route differs in simplicity, homogeneity, loading control, and structural impact. Early project assessment usually includes buffer compatibility, antibody aggregation tendency, payload reactivity, and purification feasibility before selecting the most practical conjugation strategy.
DAR or labeling degree strongly affects the performance, consistency, aggregation behavior, and signal output of antibody conjugates. A low loading level may produce insufficient detection signal or weak payload function, while excessive loading can alter antibody charge, hydrophobicity, steric profile, and antigen-binding activity. For this reason, antibody conjugates often require orthogonal characterization rather than a single test. BOC Sciences can combine UV-Vis, SEC-HPLC, HIC, LC-MS, SDS-PAGE, free payload analysis, and binding evaluation to help clients understand loading distribution and select usable conjugate fractions.
Aggregation after antibody conjugation is often associated with hydrophobic payloads, high labeling density, organic co-solvents, excessive reduction, unsuitable buffer composition, or concentrated reaction conditions. Reducing aggregation usually requires systematic optimization rather than a single adjustment. BOC Sciences can evaluate linker hydrophilicity, payload addition sequence, reaction pH, temperature, antibody concentration, solvent tolerance, purification method, and fraction selection. SEC-HPLC, DLS when needed, visual solubility checks, and binding comparison help identify conjugate fractions with lower aggregation and better application compatibility.
To design an efficient antibody conjugation workflow, clients are encouraged to provide antibody type, antibody concentration, buffer composition, stabilizers or additives, payload structure, reactive handle, target DAR or labeling degree, intended application, available material amount, and preferred analytical outputs. If previous attempts showed low coupling efficiency, high background, aggregation, poor recovery, or reduced binding, the original reaction conditions and results are also valuable. BOC Sciences uses this information to plan antibody pretreatment, linker-payload modification, conjugation conditions, purification strategy, and characterization workflow.
BOC Sciences offered a broad selection of antibodies, linkers, and payload modification options for our conjugation project. Their team helped us compare different designs and quickly identify a practical route for our target application.
— Dr. Pearson, Senior Scientist, Bioconjugation Research
The project moved smoothly from initial discussion to final product delivery in about one month. BOC Sciences handled linker preparation, antibody conjugation, purification, and testing with strong coordination and reliable execution.
— Becker, Project Manager, Biologics Development
The testing report was clear, detailed, and easy to review. It included conjugation ratio, purity, aggregation information, residual payload analysis, and binding-related results, which helped our team evaluate the conjugate with confidence.
— Dr. Crawford, Lead Assay Development Scientist
BOC Sciences kept us informed at each stage, including design confirmation, synthesis, conjugation, purification, and characterization. The timely progress updates made the project easy to track and reduced uncertainty for our team.
— Russo, Research Director, Antibody Engineering
If you have any questions or encounter issues on this page, please don't hesitate to reach out. Our support team is ready to assist you.
